Loading organizations...
§ Private Profile · Seattle, WA, USA
Precision medicine company offering genetic and hormone tests for personalized birth control recommendations, preventing side effects for women.
adyn has raised $3.0M across 1 funding round.
Key people at adyn.
adyn was founded in 2019 by Elizabeth Ruzzo (Founder).
adyn has raised $3.0M in total across 1 funding round.
Founded in 2019 by founder and CEO Elizabeth Ruzzo, adyn is a precision medicine company based in Seattle providing direct-to-consumer genetic and hormone testing to prevent adverse birth control side effects. The enterprise has raised approximately $3.25 million in venture funding, including a $2.5 million seed round backed by institutional investors including Y Combinator, Lux Capital, M13, and Anne Wojcicki. The organization analyzes an individual's biological data to offer personalized contraceptive recommendations that avoid trial-and-error, bundling these diagnostic kits with telemedicine consultations and at-home prescription delivery. Operating with seven employees, the business is actively expanding its workforce by hiring for five roles across product, marketing, and engineering. By addressing gaps in medical research for females and non-Europeans, this women's health startup aims to make scientific discovery more inclusive while facilitating reproductive healthcare access.
adyn was founded in 2019 by Elizabeth Ruzzo (Founder).
adyn has raised $3.0M in total across 1 funding round.
adyn's investors include Lux Capital, M13, Calibrate Ventures, Coalition Operators, Sound Ventures, Anne Wojcicki, Ellen Pao, Ashley Mayer, Nish Bhat, Qasar Younis, Ascend, Civilization Ventures.
adyn has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in April 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2021 | $3M Seed | LUX Capital, M13 | Calibrate Ventures, Coalition Operators, Sound Ventures, Anne Wojcicki, Ellen PAO, Ashley Mayer, Nish Bhat, Qasar Younis, Ascend, Civilization Ventures, Concrete Rose Capital, Madrona Venture Group, Y Combinator | Announced |
Key people at adyn.
adyn is a precision medicine company that has developed *The Birth Control Test*, the first at-home test designed to prevent side effects from hormonal birth control by analyzing an individual’s genetic and hormonal profile. The test measures six key hormones and over 600,000 genetic markers to assess risks for serious side effects such as blood clots and depression, enabling personalized birth control recommendations tailored to each user’s biology and health history. This approach aims to reduce the common trial-and-error process in birth control selection, which currently leads to 63% of users discontinuing pills due to side effects[1][2][4].
The product serves people seeking hormonal birth control by providing medically actionable insights through a telehealth platform, helping both patients and providers make informed decisions. adyn addresses a significant unmet need in women’s health by minimizing dangerous and unpleasant side effects, improving user satisfaction, and potentially increasing birth control adherence. The company is gaining momentum as it introduces data-driven, personalized care into a market with nearly 200 hormonal contraceptive options in the U.S.[3][6].
Founded by Dr. Elizabeth Ruzzo, a geneticist who personally experienced severe birth control side effects including depression and suicidal ideation, adyn emerged from the frustration with the current trial-and-error approach to birth control selection. Ruzzo’s scientific background and firsthand experience inspired her to create a solution that leverages genetic and hormonal data to predict side effect risks. The company was established in Seattle and has since developed a comprehensive test combining medical biography, hormone assays, and genetic screening to guide safer birth control choices[2][3][5].
Early traction includes launching the first test of its kind on the market and gaining recognition for addressing a critical gap in women’s healthcare by empowering patients and providers with precision data to avoid life-threatening side effects[8].
adyn rides the growing trend of *precision medicine* and *digital health* in women’s healthcare, addressing a longstanding unmet need for personalized contraceptive care. The timing is critical as hormonal birth control usage has declined partly due to side effect concerns, and there is increasing demand for safer, more individualized healthcare solutions. Advances in genetic testing and hormone assays, combined with telehealth, enable adyn to disrupt the traditional one-size-fits-all model of birth control prescription.
Market forces favor adyn’s approach as healthcare moves toward data-driven, patient-centered care, and as consumers seek more control and transparency over their reproductive health. By integrating genetic insights into contraceptive choice, adyn influences the broader ecosystem by setting a new standard for personalized medicine in birth control, potentially reducing adverse events and improving health outcomes at scale[2][3][6].
Looking ahead, adyn is poised to expand its impact by refining its test with more genetic markers and hormone data, broadening its user base, and deepening partnerships with healthcare providers and telehealth platforms. Trends such as increased consumer demand for personalized health solutions, advances in genomics, and the normalization of at-home testing will shape its growth trajectory.
As adyn evolves, it may influence regulatory standards and clinical guidelines for contraceptive care, driving wider adoption of precision medicine in reproductive health. Its success could inspire similar innovations across other areas of women’s health, reinforcing the shift toward individualized, data-informed healthcare decisions.
In sum, adyn’s pioneering test transforms birth control selection from a risky guessing game into a science-based, personalized process—offering safer, more effective contraception tailored to each person’s unique biology and needs[1][2][8].
